Indicatori cheie:

• EBITDA increased by 9% to RON 93.9 million
• Turnover was approximately RON 231 million in the first nine months of the year
• In the CHC segment, Biofarm ranks second in terms of volume
• Biofarm is the volume leader in 8 categories, namely for its brands Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol, Carbocit and Nervocalmin

Bucharest, November 15, 2024 – Biofarm (ticker symbol BIO), one of Romania's largest drugmakers, has announced a 9% increase in EBITDA in the first nine months of 2024 to RON 93.9 million. This result marks a significant improvement in profitability and reflects the effectiveness of the optimization measures implemented by the company, which reported a turnover of RON 231 million for the same period.

"In the first nine months of this year, we focused on increasing profitability through cost optimization and innovation in our product portfolio, which resulted in robust EBITDA growth, despite the challenges in the raw materials market. The Consumer Healthcare category continues to become increasingly competitive, but our strengthened position allows us to offer quality solutions and respond effectively to consumer needs," said Cătălin Vicol, CEO of Biofarm.

The company dominates in value in 6 key categories through its brands: Bixtonim, Triferment, Colebil, Extravalerianic, Carmol and Carbocit. In addition, Biofarm is the volume leader in no less than 8 categories, highlighting the outstanding performance of the brands Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol, Carbocit and Nervocalmin. These results confirm Biofarm's successful approach and commitment to innovation. With these achievements, the company continues to establish itself as a reliable player in Consumer Healthcare, offering effective and affordable solutions to consumers.

Biofarm has two drug manufacturing plants in Bucharest and a testing and product development unit, and its portfolio of over 100 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system). Constant innovation in the development of new products is one of the cornerstones of Biofarm's expansion and the consolidation of its position among the leaders in the pharmaceutical industry.